View source for Document:EU EMA Guidelines -

<noinclude>{{#set:
|DocReference=EU  EMA Guidelines  -
|DocValidityArea=EU
|DocScopes=HM
|DocName=EMA Guidelines
|DocVersion=-
|DocStatus=N.A.
|DocType=Corpus of texts
|DocLanguage=EN
|DocDescription=European Medicines Agency (EMA)

Examples:

- EMA/INS/GCP/112288/2023 - Guideline on computerised systems and electronic data in clinical trials

- EMA/INS/GCP/126568/2023 – Annual Report of the Good Clinical Practice [GCP) Inspectors' Working Group [IWG) 2022

- EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation [EU) No 536/2014 or the clinical trial protocol
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>

{{DocumentBox
|reference=EU  EMA Guidelines  -
|validity_area=EU
|scopes=HM
|doc_name=EMA Guidelines
|version=-
|status=N.A.
|doc_type=Corpus of texts
|language=EN
|description=European Medicines Agency (EMA)

Examples:

- EMA/INS/GCP/112288/2023 - Guideline on computerised systems and electronic data in clinical trials

- EMA/INS/GCP/126568/2023 – Annual Report of the Good Clinical Practice [GCP) Inspectors' Working Group [IWG) 2022

- EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation [EU) No 536/2014 or the clinical trial protocol
|official_link=https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines
|restricted=No
|submitted_by=Florian Adragna
|contributors=
}}